Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 1/20 | 0.51 |
| ▸ | LTB4R | Q15722 | 3/20 | 0.49 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.43 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.43 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.43 |
| ▸ | F13A1 | P00488 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2397158 | 0.89 | LMNA (0.49) | PPARALMNAPTGER1PTGER4PTGER3 | |
| SCHEMBL1206771 | 0.84 | LTB4R (0.56) | PPARALTB4RLTB4R2LMNAMAPT | |
| SCHEMBL6112724 | 0.84 | PPARA (0.52) | PPARALTB4RLTB4R2HDAC1HDAC6 | |
| SCHEMBL7827662 | 0.84 | ALOX5 (0.68) | PPARALTB4RLTB4R2HDAC1HDAC6 | |
| SCHEMBL709396 | 0.83 | LTB4R (0.59) | PPARALTB4RLTB4R2HDAC1HDAC6 | |
| SCHEMBL11706103 | 0.83 | POLB (0.42) | PPARAHDAC1HDAC6LMNA | |
| SCHEMBL6112796 | 0.82 | PPARA (0.55) | PPARALTB4RLTB4R2HDAC1HDAC6 | |
| SCHEMBL6112752 | 0.82 | PPARA (0.51) | PPARALTB4RLTB4R2HDAC1HDAC6 | |
| SCHEMBL31114215 | 0.82 | PPARA (0.51) | PPARALTB4RLTB4R2HDAC1HDAC6 | |
| SCHEMBL4426553 | 0.81 | POLB (0.42) | PPARALTB4RF13A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120130129-A1 | Efficient Method for Preparing Functionalized Benzosuberenes | BAYLOR UNIVERSITY (US) | 2012-05-24 | — | — | US | disclosed |
| WO-2012068284-A2 | EFFICIENT METHOD FOR PREPARING FUNCTIONALIZED BENZOSUBERENES | BAYLOR UNIVERSITY (US) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130129-A1 | Efficient Method for Preparing Functionalized Benzosuberenes | CYP2B6, CYP2A6, GABRA6 | PPARA 153/4885LTB4R 743/4885LTB4R2 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.